In the realm of CD47 targeted therapy for ovarian cancer, various approaches have been explored, ranging from monotherapy inhibiting the CD47-SIRPα axis to combinations with tumor-targeting antibodies and bispecific antibodies disrupting the CD47-SIRPα axis (30). This evidence concerns the gene CD47 and neoplasm.